pyrazole has been researched along with Obesity in 5 studies
1H-pyrazole : The 1H-tautomer of pyrazole.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pyrazole nucleus is a unique structural scaffold which acts as an interesting template for combinatorial as well as medicinal chemistry." | 2.58 | The Synthetic and Biological Attributes of Pyrazole Derivatives: A Review. ( Dwivedi, J; Jain, S; Sharma, S; Singh, A, 2018) |
| "Presently, obesity is one of the major health problems in the developed as well as developing countries due to lack of physical work and increasing sedentary life style." | 2.50 | Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists. ( Giridhar, R; Kanhed, AM; Murumkar, PR; Sharma, MK; Yadav, MR, 2014) |
| "Obesity is a growing health problem in the United States." | 1.34 | Induction of cytochrome P450 2E1 [corrected] promotes liver injury in ob/ob mice. ( Cederbaum, AI; Dey, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dwivedi, J | 1 |
| Sharma, S | 1 |
| Jain, S | 1 |
| Singh, A | 1 |
| Sharma, MK | 1 |
| Murumkar, PR | 1 |
| Kanhed, AM | 1 |
| Giridhar, R | 1 |
| Yadav, MR | 1 |
| Devasthale, P | 1 |
| Wang, W | 1 |
| Hernandez, AS | 1 |
| Moore, F | 1 |
| Renduchintala, K | 1 |
| Sridhar, R | 1 |
| Pelleymounter, MA | 1 |
| Longhi, D | 1 |
| Huang, N | 1 |
| Flynn, N | 1 |
| Azzara, AV | 1 |
| Rohrbach, K | 1 |
| Devenny, J | 1 |
| Rooney, S | 1 |
| Thomas, M | 1 |
| Glick, S | 1 |
| Godonis, H | 1 |
| Harvey, S | 1 |
| Cullen, MJ | 1 |
| Zhang, H | 1 |
| Caporuscio, C | 1 |
| Stetsko, P | 1 |
| Grubb, M | 1 |
| Huang, C | 1 |
| Zhang, L | 1 |
| Freeden, C | 1 |
| Li, YX | 1 |
| Murphy, BJ | 1 |
| Robl, JA | 1 |
| Washburn, WN | 1 |
| Lange, JH | 1 |
| Kruse, CG | 1 |
| Dey, A | 1 |
| Cederbaum, AI | 1 |
2 reviews available for pyrazole and Obesity
| Article | Year |
|---|---|
The Synthetic and Biological Attributes of Pyrazole Derivatives: A Review.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Antineoplastic Agents; Antiox | 2018 |
Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists.
Topics: Animals; Anti-Obesity Agents; Dose-Response Relationship, Drug; Humans; Molecular Structure; Obesity | 2014 |
3 other studies available for pyrazole and Obesity
| Article | Year |
|---|---|
Dihydropyrrolopyrazol-6-one MCHR1 antagonists for the treatment of obesity: Insights on in vivo efficacy from a novel FLIPR assay setup.
Topics: Animals; Anti-Obesity Agents; Half-Life; Humans; Obesity; Protein Binding; Pyrazoles; Rats; Rats, Sp | 2015 |
Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives.
Topics: Animals; Anti-Obesity Agents; CHO Cells; Cricetinae; Cricetulus; Humans; Imidazoles; Isomerism; Mode | 2008 |
Induction of cytochrome P450 2E1 [corrected] promotes liver injury in ob/ob mice.
Topics: Acetone; Animals; Apoptosis; Caspase 3; Catalysis; Chemical and Drug Induced Liver Injury; Cytochrom | 2007 |